Migraine Drugs Market by Product Type (Acute migraine treatment, Preventive migraine treatment), Route of administration (Oral, Injection, and Others), and End User (Hospital pharmacies, Retail pharmacies, Online pharmacies) - Global Forecast to 2023
North America dominates the migraine drugs market with the North America accounted major market share in 2017. Established healthcare infrastructure; and increasing demand for preventive migraine treatment options are some of the major driving factors driving the growth of this market in North America. The Asian migraine drugs market is poised to grow at the highest CAGR during the forecast period owing to improving healthcare infrastructure and rising awareness about novel treatments among people in the region. The rising focus of prominent players on the Asian migraine drugs market is another factor driving its growth. Furthermore, emerging countries such as India and China provides immense growth opportunities to the migraine drug manufacturers.
Prominent players in the suture anchor devices market Abbott Laboratories (U.S.), Allergan (Ireland), Amgen (U.S.), GlaxoSmithKline (UK), Pfizer (U.S.), Eli Lilly (U.S.), Aegis Therapeutics, LLC. (U.S.), Johnson and Johnson (U.S.), and AstraZeneca PLC. (UK).
Scope of the Report
This research report covers the global Migraine Drugs market by method; product type; route of administration; end user; and geography.
Migraine Drugs Market, by Product Type
- ACute migraine treatment
- Preventive migraine treatment
- BEta Blockers
- Anti-serotonergic drugs
- Calcium Channel Blockers
Migraine Drugs Market, by Route of Administration
Migrane Drugs Market, by End User
- hospitals based pharmacies
- retail pharmacies
- online pharmacies
Migrane Drugs Market, BY region
- North america
- rest of europe (roe)
- Asia pacific
- rest of asia pacific
- Rest of the world (roW)
Growth opportunities and latent adjacency in Migraine Drugs Market